Views & Analysis 5 years of biosimilars in the US: what have we learned? Biologics have created revolutionary treatment options that have transformed the care journey for hundreds of millions of patients worldwide.
Views & Analysis Who could replace Sir Andrew Dillon at NICE? With Sir Andrew Dillon announcing his retirement as chief executive of NICE, pharmaphorum discusses potential replacements for the man who is arguably the most influential figure in health
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends